

Parkinson's Action Network
1025 Vermont Avenue, NW • Suite 1120
Washington, DC 20005
E-Mail: info@parkinsonsaction.org
Phone: 202.638.4101 • 800.850.4726
Fax: 202.638.7257
Website: www.parkinsonsaction.org

January 28, 2005

Dr. Roger Perlmutter
Executive Vice-President,
Research and Development
Amgen, Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320

Dear Dr. Perlmutter:

On behalf of the advocates and Board of Directors of the Parkinson's Action Network, I am writing to indicate our strong interest in the requests of GDNF clinical trial participants who wish to continue their treatment to have that therapy reinstated. In particular, PAN supports the claim of those trial participants who wish to continue with the treatment and accordingly request the Amgen Corporation, the manufacturer of GDNF, to reinstate GDNF therapy for those patients and their physicians who:

- (i) request it;
- (ii) are prepared to sign appropriate waivers that will hold Amgen harmless in the event of complications and side-effects, whether known or unforeseen, and whether they occur now or at any time in the future;
- (iii) provide continuing data on the patients' experience with GDNF that will enable scientists and regulatory authorities to monitor the safety and efficacy of the treatment.

While we recognize the myriad of concerns regarding continued access to GDNF, we strongly urge Amgen to show its compassion for these Parkinson's patients and their families, and the entire Parkinson's community, by granting this request.

I appreciate your consideration and look forward to working with you in the future.

Sincerely,

Amy L. Comstock
Executive Director